Clinical Report: Long-Term PDS Data Show Sustained Disease Control

Overview

Long-term data on the port delivery system (PDS) for neovascular age-related macular degeneration (nAMD) indicates sustained vision maintenance and effective fluid control over 5 to 7 years. The incidence of endophthalmitis was reported at 2.8% over 8 years.

Background

The management of nAMD is critical due to its potential to cause significant vision loss. Traditional treatment involves frequent intravitreal injections, which can be burdensome for patients. The port delivery system offers a novel approach to deliver continuous therapy.

Data Highlights

No numerical data available in the source material.

Key Findings

• Continuous therapy with the PDS maintains vision for 5 to 7 years.
• 85% of patients experienced no intraretinal fluid during the study.
• The incidence of endophthalmitis was reported at 2.8% over 8 years.
• Refill intervals can vary, with some clinicians opting for every 6 months, while others may extend to 9 months or longer.

Clinical Implications

The PDS may provide a viable alternative to frequent injections for nAMD, potentially reducing treatment burden. Clinicians should consider the long-term safety profile and refill intervals when implementing this therapy.

Conclusion

The long-term data on the PDS includes findings on vision maintenance and safety profile.

Related Resources & Content

1. Diana V. Do, Jeremy Wolfe, MD, MS, Retinal Physician, 2026 -- Long-Term PDS Data Show Sustained Disease Control
2. American Academy of Ophthalmology, Age-Related Macular Degeneration Preferred Practice Pattern®, 2024 -- Guidance and regulatory status
3. ASCO Publications — Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
4. Retinal Physician — PDS May Reduce Treatment Burden in High-Need Patients Recommendations
5. Clinical Research in Cardiology — Long-term Treatment Adherence, Cholesterol Reduction, and Three-Year Clinical Outcomes in Patients with Extremely High Cardiovascular Risk Treated with PCSK9 Monoclonal Antibodies
6. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
7. PDS May Reduce Treatment Burden in High-Need Patients Recommendations
8. Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
9. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results - Ophthalmology
10. 5.1 **Endophthalmitis**